Can-Fite BioPharma (CANF) EBITDA (2014 - 2023)
Can-Fite BioPharma's (CANF) quarterly EBITDA came in at -$1.8 million in Q4 2023, down 55.16% YoY from -$4.1 million in Q4 2022, and up 1.66% on a QoQ basis from -$1.9 million in Q3 2023.
Can-Fite BioPharma (CANF) EBITDA (2014 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 10 years of EBITDA data on file, last reported at -$1.8 million in Q4 2023.
- Quarterly EBITDA fell 55.16% year-over-year to -$1.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$8.2 million (changed 0.0% YoY) and the FY2025 annual result came in at -$10.0 million, down 22.39% from the prior year.
- EBITDA rose to -$1.8 million in Q4 2023, from -$1.9 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $1.7 million in Q1 2019 to a low of -$6.3 million in Q2 2019.
- A 5-year average of -$2.8 million and a median of -$2.6 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2019 — EBITDA sank 533.39% — and 2022, when it surged 70.66%.
- Tracing CANF's EBITDA over 5 years: stood at -$4.6 million in 2019, then increased by 22.95% to -$3.6 million in 2020, then declined by 13.37% to -$4.0 million in 2021, then jumped by 70.66% to -$1.2 million in 2022, then plunged by 55.16% to -$1.8 million in 2023.
- The last three EBITDA figures came in at -$1.8 million (Q4 2023), -$1.9 million (Q3 2023), and -$1.8 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | Can-Fite BioPharma | 2.78 Mn | -8.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1.83 Mn |
| Sep 30, 2023 | -1.87 Mn |
| Jun 30, 2023 | -1.78 Mn |
| Mar 31, 2023 | -2.71 Mn |
| Dec 31, 2022 | -1.18 Mn |
| Sep 30, 2022 | -2.57 Mn |
| Jun 30, 2022 | -2.07 Mn |
| Mar 31, 2022 | -2.37 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | -3.51 Mn |
| Jun 30, 2021 | -3.13 Mn |
| Mar 31, 2021 | -2.17 Mn |
| Dec 31, 2020 | -3.55 Mn |
| Sep 30, 2020 | -2.48 Mn |
| Jun 30, 2020 | -3.83 Mn |
| Mar 31, 2020 | -4.28 Mn |
| Dec 31, 2019 | -4.61 Mn |
| Sep 30, 2019 | -2.79 Mn |
| Jun 30, 2019 | -6.32 Mn |
| Mar 31, 2019 | 1.71 Mn |